ALKS: Alkermes Plc
About
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Key Details
Market Cap
$4.45B
P/E Ratio
14
1Y Stock Return
15.66%
1Y Revenue Growth
-5.37%
Dividend Yield
0.00%
Price to Book
3.4
Strategies that include ALKS
Stock's related to ALKS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NNOX | 42.65% | $332.87M | -7.63% | 0.00% |
| DNOW | 41.74% | $1.52B | +40.10% | 0.00% |
| MSEX | 40.80% | $1.18B | +2.56% | 1.99% |
| SCL | 40.57% | $1.69B | -6.79% | 2.01% |
| CRSP | 40.39% | $4.01B | -30.49% | 0.00% |
| BPMC | 40.28% | $6.01B | +42.68% | 0.00% |
| PEGA | 39.81% | $7.36B | +65.88% | 0.14% |
| BBIO | 39.61% | $4.26B | -20.38% | 0.00% |
| SLVM | 39.26% | $3.55B | +82.37% | 1.72% |
| FBNC | 38.94% | $1.87B | +46.57% | 1.95% |
| SJW | 38.57% | $1.83B | -14.15% | 2.89% |
| OTTR | 37.85% | $3.35B | +6.14% | 2.35% |
| VIR | 37.65% | $954.40M | -26.51% | 0.00% |
| SBSI | 36.61% | $1.07B | +25.26% | 4.11% |
| KAI | 36.42% | $4.65B | +51.38% | 0.32% |
| SFBS | 36.33% | $5.11B | +85.58% | 1.29% |
| NTCT | 36.28% | $1.52B | +3.77% | 0.00% |
| APPN | 36.21% | $2.72B | -0.51% | 0.00% |
| PGEN | 36.18% | $228.91M | -28.00% | 0.00% |
| FCF | 36.10% | $1.89B | +40.91% | 2.77% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BCS | 0.09% | $47.29B | +83.45% | 3.18% |
| PRPH | -0.12% | $18.14M | -82.61% | 0.00% |
| YPF | -0.13% | $13.98B | +139.72% | 0.00% |
| NOK | -0.14% | $22.63B | +17.56% | 3.29% |
| OBDC | -0.20% | $5.86B | +4.58% | 10.23% |
| HTGC | -0.28% | - | - | 8.42% |
| PENG | -0.29% | $911.79M | +4.97% | 0.00% |
| BSM | -0.31% | $3.17B | -13.01% | 10.65% |
| PSQH | -0.32% | $79.26M | -57.46% | 0.00% |
| GD | -0.35% | $77.26B | +14.02% | 1.98% |
| BROS | -0.37% | $5.67B | +74.77% | 0.00% |
| PWR | 0.39% | $48.83B | +80.40% | 0.11% |
| BCAN | 0.42% | $72.87M | -99.75% | 0.00% |
| TTE | -0.42% | $138.45B | -11.95% | 5.50% |
| NNE | 0.48% | $833.66M | +531.50% | 0.00% |
| KGS | -0.48% | $3.37B | +110.22% | 4.11% |
| EQNR | 0.50% | $64.72B | -22.63% | 5.56% |
| SNPS | -0.50% | $82.03B | -1.18% | 0.00% |
| CX | -0.51% | $8.22B | -20.23% | 0.00% |
| TRVG | -0.55% | $37.05M | -37.92% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MNR | -17.56% | $1.66B | -10.71% | 15.90% |
| CEPU | -11.89% | $2.07B | +87.28% | 0.00% |
| VIST | -11.76% | $4.75B | +67.10% | 0.00% |
| WM | -11.07% | $87.92B | +27.58% | 1.34% |
| TGS | -9.72% | $1.97B | +116.04% | 0.00% |
| MANU | -9.55% | $2.88B | -9.41% | 0.00% |
| RBRK | -9.10% | $8.03B | +38.16% | 0.00% |
| MSFT | -9.06% | $3.11T | +11.99% | 0.54% |
| HLF | -9.04% | $778.11M | -38.09% | 0.00% |
| VZIO | -8.62% | $2.29B | +67.76% | 0.00% |
| VRT | -8.56% | $52.90B | +230.61% | 0.07% |
| MNOV | -8.51% | $93.19M | +2.15% | 0.00% |
| CYD | -8.51% | $364.46M | -2.94% | 4.26% |
| TCTM | -8.43% | $8.10M | -42.99% | 0.00% |
| RDDT | -8.01% | $24.08B | +303.41% | 0.00% |
| LOMA | -7.99% | $1.31B | +66.67% | 0.00% |
| SRRK | -7.38% | $2.61B | +134.91% | 0.00% |
| GOOGL | -7.32% | $2.18T | +30.04% | 0.23% |
| BKNG | -6.87% | $164.72B | +58.25% | 0.53% |
| WST | -6.87% | $22.02B | -13.73% | 0.27% |
ETF's related to ALKS
News
SeekingAlpha
November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.
Yahoo
Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences.
Yahoo
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the
Yahoo
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.
Yahoo
Alkermes ( NASDAQ:ALKS ) Third Quarter 2024 Results Key Financial Results Revenue: US$378.1m (flat on 3Q 2023). Net...
Yahoo
Alkermes PLC (ALKS) reports robust revenue growth driven by Vivitrol and Lybalvi, while navigating market challenges and investing in future opportunities.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.